📊 COCP Key Takeaways
Investment Thesis
Cocrystal Pharma exhibits severe financial distress with collapsing revenue (-69.3% YoY), massive operating losses (-$6.5M), and negative free cash flow despite holding $7.7M in cash. The company's long-term debt of $49.9M far exceeds stockholders' equity, creating unsustainable leverage that threatens viability without significant operational turnaround or capital injection.
COCP Strengths
- Maintains adequate liquidity with 5.78x current ratio and $7.7M cash on hand
- Positive gross margin of 100.4% indicates viable product economics when revenue materializes
- 13 Form 4 insider filings suggest management engagement, though activity level does not offset fundamental concerns
COCP Risks
- Revenue collapse of 69.3% YoY indicates failed clinical trials, loss of partnerships, or failed commercialization
- Debt-to-equity ratio of 6.51x with long-term debt of $49.9M versus equity of $7.6M indicates bankruptcy risk within 12-18 months without turnaround
- Negative operating cash flow of -$6.5M and free cash flow margin of -321.2% means cash burn will deplete reserves within approximately 14 months at current burn rate
- Pharmaceutical sector typically requires years to achieve profitability; current trajectory unsustainable
Key Metrics to Watch
- Quarterly revenue trend and pipeline progress announcements
- Monthly cash burn rate and runway to profitability or financing event
- Debt covenant compliance and refinancing requirements
COCP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.78x current ratio provides a solid financial cushion.
COCP Profitability Ratios
COCP vs Healthcare Sector
How Cocrystal Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COCP Balance Sheet & Liquidity
COCP 5-Year Financial Trend
5-Year Trend Summary: Cocrystal Pharma, Inc.'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-1.87 indicates the company is currently unprofitable.
COCP Growth Metrics (YoY)
COCP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $489.0K | -$2.0M | N/A |
| Q2 2021 | $554.0K | -$2.0M | N/A |
| Q1 2021 | $461.0K | -$2.0M | $-0.04 |
| Q3 2020 | $489.0K | -$324.0K | N/A |
| Q2 2020 | $554.0K | $1.5M | $0.05 |
| Q1 2020 | $461.0K | -$2.0M | $-0.05 |
| Q3 2019 | $492.0K | -$324.0K | N/A |
| Q2 2019 | $592.0K | -$1.3M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COCP Capital Allocation
COCP SEC Filings
Access official SEC EDGAR filings for Cocrystal Pharma, Inc. (CIK: 0001412486)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COCP
What is the AI rating for COCP?
Cocrystal Pharma, Inc. (COCP) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COCP's key strengths?
Maintains adequate liquidity with 5.78x current ratio and $7.7M cash on hand. Positive gross margin of 100.4% indicates viable product economics when revenue materializes.
What are the risks of investing in COCP?
Revenue collapse of 69.3% YoY indicates failed clinical trials, loss of partnerships, or failed commercialization. Debt-to-equity ratio of 6.51x with long-term debt of $49.9M versus equity of $7.6M indicates bankruptcy risk within 12-18 months without turnaround.
What is COCP's revenue and growth?
Cocrystal Pharma, Inc. reported revenue of $2.0M.
Does COCP pay dividends?
Cocrystal Pharma, Inc. does not currently pay dividends.
Where can I find COCP SEC filings?
Official SEC filings for Cocrystal Pharma, Inc. (CIK: 0001412486) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COCP's EPS?
Cocrystal Pharma, Inc. has a diluted EPS of $-0.61.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.